Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pazopanib (GSK)
- Development stage
- Unknown
- Lead developer
- Center Trials & Treatment
- Modality
- Small Molecules
- Administration
- Intranasal, Oral
01
Overview
**Pazopanib** is an orally available, small-molecule, multi-target receptor tyrosine kinase inhibitor originally developed by GlaxoSmithKline and subsequently acquired by Novartis. It inhibits VEGF receptors 1, 2, and 3, platelet-derived growth factor receptors alpha and beta, and KIT, thereby suppressing tumor angiogenesis and growth-factor signaling. It is marketed as Votrient for adults with advanced renal cell carcinoma and for advanced soft-tissue sarcoma after prior chemotherapy. In the specified Center Trials & Treatment Phase 1 study, pazopanib was an individual active component of investigational intranasal NST-4G for recurrent glioblastoma, gliosarcoma, and anaplastic glioma. ([accessdata.fda.gov](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022465s036lbl.pdf))
- Brand names
- Votrient
- Other names
- pazopanib hydrochloride
02
Targets
CSF1R (Macrophage colony-stimulating factor receptor)FGFR1 (Fibroblast growth factor receptor 1)FGFR3 (Fibroblast growth factor receptor 3)ITK (Interleukin 2-inducible T-cell kinase)LCK (Proto-oncogene tyrosine-protein kinase Lck)PDGFRA (Platelet-derived growth factor receptor alpha)PDGFRB (Platelet-derived growth factor receptor beta)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)
Beyond the preview
Go deeper on pazopanib (GSK).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pazopanib (GSK).